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ABSTRACT:  The association between overt hypothyroidism (OH) and altered lipid 
profile is well known, however the significance of dyslipidemia in subclinical 
hypothyroidism (SCH) remain controversial. Therefore, this study was conducted to 
determine any association between lipid profile and different degrees of thyroid 
dysfunction. Thyroid and lipid profile parameters were analysed in 58 patients with overt 
(TSH  ≥ 10.0 µIU/L and/or abnormally low fT4 and fT3 levels) and 87 patients with 
subclinical hypothyroidism (TSH 6.0-9.9 µIU/L with normal fT4 and fT3 levels) in this 
case-control study. These were compared with 100 age- and sex-matched euthyroid 
controls. It was found that only mean serum level of total cholesterol in patients with SCH 
was significantly high from that in controls (p=0.045). Other lipid parameters did not show 
any statistical significance. Whereas patients with OH had statistically significant higher 
levels of total cholesterol (p<0.001), triglyceride (p<0.05), LDL-C (p<0.001) and VLDL-C 
(p<0.05). There was also an increase in HDL-C in both SCH and OH group though not 
significant statistically. In conclusion, lipid profile is not much deranged in SCH whereas 
OH is a major cause of secondary dyslipidemia which may lead to increased risk of 
coronary artery disease. Therefore, thyroid hormone replacement would be most beneficial 
in patients with OH instead of SCH. However, patients with SCH should be monitored for 
deterioration of thyroid function and dyslipidemia at regular intervals. 
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INTRODUCTION
ᴪ 
 
Primary hypothyroidism is a graded phenomenon 
with different levels of severity, showing a wide 
inter-individual range of clinical and biochemical 
presentation. Hypothyroidism results from reduced 
secretion of thyroxine (T4) and triiodothyronine 
(T3) from the thyroid gland
1. Biochemically 
decrease in T4 and T3 concentrations lead to hyper 
secretion of pituitary TSH and an amplified 
increase in serum TSH levels. This is a key 
laboratory finding, particularly in the early 
detection of thyroid failure. 
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Subclinical hypothyroidism (SCH), also called mild 
hypothyroidism, is a term used for a condition in 
which there are small elevations in TSH, yet 
normal circulating levels of thyroid hormones. This 
condition is more common in the elderly and is 
found twice as often in women as in men
2,3. While 
it is uncommon in younger persons, by the age of 
65 years, the overall prevalence of the disorder is 
about 17% in women and 7% in men
4. SCH has 
been detected with increasing frequency in recent 
years and is causing major controversies 
concerning management and treatment. SCH is 
usually detected during biochemical screening for 
nonspecific symptoms by TSH measurements
5, 
especially in tertiary care hospitals. 
Overt hypothyroidism (OH) is associated with 
abnormalities of lipid metabolism, which may 
predispose to the development of atherosclerotic 
coronary artery disease (CAD)
6,7. Whether SCH 
also has any demonstrable effect on serum lipid Saini et al / Association between different degrees of Hypothyroidism and Serum Lipids 
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concentrations has been controversial
8-15. Some 
studies of patients with subclinical hypothyroidism 
have shown that patients have elevations in their 
cholesterol levels
16,17. However, a precise 
relationship between different degrees of 
hypothyroidism and CAD has not been confirmed. 
This study was, therefore, planned to evaluate the 
changes in biochemical lipid profile parameters in 
subclinical and overt hypothyroid subjects, and to 
correlate these values with thyroid profile (TSH, 
fT3 and fT4) of the patient. 
 
METHODOLOGY 
 
Study population 
 
The study was conducted on 245 ambulatory 
subjects of age group 20 to 50 years referred to 
thyroid clinic in a tertiary care hospital of northern 
India after being approved by institutional review 
board. After informed consent, brief clinical history 
and examination was done to rule out renal 
disorders, liver disorder, or any other inflammatory 
condition which would have influenced the 
parameters under study. 
For these analyses, we excluded subjects who were 
receiving concurrent treatment with drugs that 
could contribute to hypothyroidism (lithium, 
amiodarone, or iodine), those receiving antithyroid 
medication (methimazole or propylthiouracil) for 
hyperthyroidism and treatment with lipid lowering 
drugs for dyslipidemia. 
After overnight fasting, 6ml venous blood sample 
was collected. After centrifugation (10 min at 3000 
x g), serum was divided into aliquots for lipid 
profile parameters and thyroid function tests (TSH, 
fT3 and fT4). Both the aliquots were independently 
analyzed, such that the person analysing lipid 
profile was unaware of patient’s thyroid function 
test results and vice versa. Sample for lipid profile 
was analyzed immediately. Samples for thyroid 
function tests were stored at -40ºC until batch 
analysed.  
 
Lipid Profile tests 
 
Serum total cholesterol (TC) was analyzed by 
enzymatic CHOD-PAP method and triglyceride 
(TG) was estimated by GPO-PAP method using 
diagnostic kits by Randox Laboratories (Crumlin, 
United Kingdom) on Synchron CX4 and CX9 
autoanalyzer (Beckman  Coulter, USA). High-
density lipoprotein cholesterol (HDL-C) was 
determined directly using system pack kits from 
Beckman Coulter. Low density lipoprotein 
cholesterol (LDL-C) was calculated using the 
Friedewald formula
18. 
 
 
 
Thyroid function tests 
 
Serum TSH, fT4 and fT3 were assayed using fully 
automated chemiluminescent immunoassay Access 
2 by Beckman and Coulter (USA). Reference 
intervals provided by the manufacturer were TSH 
0.34-5.6µIU/L, fT3 2.5-3.9pg/mL and serum fT4 
0.6-1.12ng/dL. The sensitivities of the TSH, fT3, 
and fT4 were 0.0025µIU/L, 1 pg/mL, and 0.4ng/dL 
respectively. The intraassay coefficients of 
variation for TSH, fT3 and fT4 were 1.7%, 2.7%, 
and 3.2% respectively. 
After conducting thyroid function tests, subjects 
having euthyroid state (n=100, TSH≤ 6.0µIU/ml, 
normal fT3 and fT4 levels) were taken as controls. 
Patients with TSH levels >6.0μIU/ml were 
considered as hypothyroid (n=145).  These patients 
were further divided into sub-clinical hypothyroid 
(n=87; TSH- 6.1 to 9.9μIU/ml with normal fT4 and 
fT3 levels) and overt hypothyroid (n=58 with TSH 
≥10μIU/ml and/or abnormally low fT4 and fT3 
levels). 
 
Statistical analysis 
 
Statistical analysis was carried out using SPSS for 
windows 15.0 software (SPSS Inc, Chicago, IL, 
USA). Continuous variables were expressed as 
mean ± standard error of mean (S.E.M.). One way 
analysis of variance (ANOVA) and student’s t test 
was applied to the data. The Pearson correlation 
was used to test whether TSH, fT4 and fT3 was 
correlated with TC, LDL-C, HDL-C, TG, VLDL-
C, TC/HDL-C and LDL/HDL-C.  P value <0.05 
was considered statistically significant. 
 
RESULT 
 
In our study population, both the hypothyroid and 
control groups were age and sex-matched. Majority 
of the patients and the controls were women, since 
the hospital is popular mainly for its gynecology 
and obstetrics services. Mean age of the 
hypothyroid patients was 31.55 ± 2.1 years and that 
of euthyroid group was 30.76 ± 1.9 years. 
Hypothyroid group consisted of 80.22% women 
whereas the euthyroid group had 78% women. 
Mean serum TSH level in the control group was 
2.428 ± 0.11μIU/ml  (table 1). The subclinical 
hypothyroid (7.615 ± 0.1μIU/ml) patients showed 
significant increase in TSH levels and it was much 
more significant in overt hypothyroid cases (39.758 
± 4.46μIU/ml) when compared with controls. The 
levels of fT4 (0.84 ± 0.03ng/dL) and fT3 (3.08 ± 
0.07pg/dL) decreased slightly in subclinical 
hypothyroid patients as compared to the 
corresponding values in controls (0.94 ± 0.03ng/dL 
and 3.20± 0.04pg/dL respectively) but this was   
significant statistically. In overt hypothyroid cases, 
fT3 and fT4 (2.60 ± 0.07pg/dL and 0.43 ± Saini et al / Association between different degrees of Hypothyroidism and Serum Lipids 
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0.1532ng/dL respectively) levels showed a highly 
significant decrease as compared to the control 
group. 
 
Table 1: Comparison between the TSH, fT4 and 
fT3 values obtained in hypothyroid and 
euthyroid subjects 
 
 Euthyroid  SCH  OH 
TSH 
(μIU/ml) 
2.428 ± 
0.11 
7.615 ± 
0.11** 
39.758 ± 
4.46** 
fT4 
(pg/dl) 
0.943 ± 
0.03 
0.84 ± 
0.03* 
0.43 ± 
0.02** 
fT3 
(ng/ml) 
3.205 ± 
0.04 
3.08 ± 
0.07* 
2.60 ± 
0.07** 
*p value vs controls <0.05; **p value vs controls 
<0.001 
 
Mean serum level of TC in patients with SCH 
(236.724 ± 9.47mg/dl) was significantly high from 
that of value in controls (179.133 ± 6.69mg/dl) 
(p=0.045) (table 2). All other parameters were not 
statistically significant as compared to the controls. 
Patients with OH had statistically significant higher 
levels of TC (260.04 ± 11.07mg/dl, p<0.001), TG 
(171.76 ± 1.8mg/dl, p<0.05), LDL-C (151.635 ± 
8.44mg/dl, p<0.001) and VLDL-C (34.35 ± 
4.06mg/dl, p<0.05) when compared with controls. 
There was an increase in HDL-C in both SCH and 
OH group though not significant statistically. LDL-
C/HDL-C and TC/HDL-C ratios were also not 
significant statistically in either group.  When 
subclinical and overt hypothyroid cases were 
compared, TSH, fT3 and fT4 values showed a 
statistical significance. The mean levels of 
atherogenic lipid variables were greater in OH than 
in SCH, although the differences did not reach 
statistical significance. 
 
Table 2: Lipid parameters in patients with hypothyroidism vs controls 
 
Parameters  Control  SCH  p value*  OH  p value** 
TC  
LDL-C  
HDL-C  
VLDL-C 
TG  
TC/HDL-C 
LDL/HDL 
179.133 ± 6.697 
113.840 ± 8.467 
41.500 ± 3.126 
23.133 ± 2.483 
115.667 ± 8.022 
4.643 ± 0.404 
3.035 ± 0.344 
236.724 ± 9.472 
154.193 ± 17.042 
45.296 ± 3.783 
33.296 ± 1.995 
166.48 ± 7.481 
5.798 ± 0.757 
3.843 ± 0.669 
0.045 
0.212 
0.476 
0.115 
0.115 
0.278 
0.624 
260.043 ± 11.073 
151.635 ± 8.446 
49.059 ± 3.494 
34.35 ± 4.068 
171.761 ± 1.800 
5.132 ± 0.514 
3.439 ± 0.38 
0.000 
0.001 
0.125 
0.041 
0.041 
0.281 
0.232 
*SCH vs control; **OH vs controls 
 
Correlation coefficients (r) between TSH, fT3 and 
fT4 levels, and lipid parameters were also 
calculated to find if any association exists between 
them. No correlation was found in any of the 
parameters in SCH except HDL which showed a 
negative correlation with fT4 (table 3). Other 
parameters did not show any statistically significant 
correlation.
 
Table 3: Correlation of lipid profile parameters with thyroid function in subclinical hypothyroid cases 
 
             TSH             ft4            ft3 
r values      p value  r values      p value  r values      p value 
TC  0.033 0.830 -0.004  0.978 -0.007  0.952 
LDL-C -0.278  0.236  -0.089  0.736  0.212  0.278 
HDL-C -0.144  0.544  -0.519  0.005  0.108  0.591 
VLDL-C  0.156 0.312 0.057 0.630 -0.151  0.208 
TG  0.156 0.312 0.057 0.630 -0.151  0.208 
TC/HDL-C  0.359 0.120 0.337 0.086 0.005  0.979 
LDL-C/HDL-C 0.158 0.518 0.203 0.321 0.052  0.801 Saini et al / Association between different degrees of Hypothyroidism and Serum Lipids 
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In OH group, TSH showed a positive correlation 
(p<0.05) and fT4 levels showed a negative 
correlation with TC (table 4). There was also 
negative correlation of serum HDL-C and 
fT4.Moreover, fT3 also showed significant 
negative correlation with TC/HDL-C and 
LDL/HDL-C ratios in OH cases (p<0.05).
 
Table 4: Correlation of lipid profile parameters with thyroid function in overt hypothyroid cases 
 
             TSH             fT4            fT3 
r values      p value  r values      p value  r values      p value 
TC  0.315 0.035 -0.264  0.023 -0.098  0.952 
LDL-C  0.127 0.628 -0.282  0.512 -0.237  0.278 
HDL-C -0.010  0.969  -0.447  0.017  0.398  0.114 
VLDL-C  0.139 0.362 0.078 0.512 -0.115  0.452 
TG  0.139 0.362 0.078 0.146 -0.115  0.452 
TC/HDL-C  0.013 0.959 0.343 0.074 -0.541  0.025 
LDL-C/HDL-C 0.031 0.906 0.214 0.275 -0.526  0.030 
 
DISCUSSION 
 
The data in our study shows that the mean age of 
the hypothyroid subjects was 31.55 ± 2.1 years, 
majority were women, and prevalence of 
hypothyroidism (overt and subclinical) was high in 
this group. The hypothyroidism in young adult 
women could be iodine deficiency- related as at 
this age, Hashimoto’s disease is most unlikely. 
In our study, it was found that patients with OH 
had significantly higher levels of TC, LDL-C, TG 
and VLDL-C as compared to control group. 
Moreover, there was positive correlation of TC 
with TSH level (p=0.035) and negative correlation 
with fT4 (p=0.023) in overt hypothyroid group. 
However, in SCH patients, only TC was slightly 
high (p=0.045) as compared to the controls. The 
explanation for these observed findings lie in the 
fact that thyroid hormones regulate the activity of 
some key enzymes in lipoprotein transport and 
therefore alter the lipoprotein levels in 
hypothyroidism. The primary mechanism for 
hypercholesterolemia in hypothyroidism is 
accumulation of LDL cholesterol due to a reduction 
in the number of cell surface receptors for LDL
19, 
resulting in decreased catabolism of LDL. The 
promoter of the LDL receptor gene contains a 
thyroid hormone responsive element (TRE) which 
allows the triiodothyronine (T3) to upregulate the 
gene expression of the LDL receptor
20. 
Furthermore, decreased thyroid function not only 
increases the number of LDL particles but also 
promotes LDL oxidability
21,22. 
Hypertriglyceridemia associated with increased 
levels of VLDL is attributable to the decreased 
activity of lipoprotein lipase, which results in a 
decreased clearance of triglyceride-rich 
lipoproteins
23. Thus, hypothyroidism is a major 
cause of secondary dyslipidemia, and may 
represent an increased risk for coronary heart 
disease. 
It is interesting to note that in the levels of HDL 
were progressively increased from euthyroid to 
SCH to OH, though not statistically significant. 
Further, there was increase in TC/HDL-C and 
LDL-C/HDL-C ratios in both the hypothyroid 
groups as compared to the controls which 
emphasizes the fact that the increased HDL alone 
does not protect against coronary heart disease
24. 
Plasma HDL concentrations have been reported to 
be elevated in severe hypothyroidism
25-27. These 
conflicting results are partly because of the recently 
reported regulation of cholesterol ester transfer 
protein (CETP) and hepatic lipase (HL) activity by 
thyroid hormone
24. CETP transports cholesteryl 
esters from HDL2 to VLDL, IDL and remnants, 
and replaces it with triglycerides
28. HDL2 is 
consequently hydrolyzed and converted to HDL3 
by HL. The activity of CETP and HL are low in 
hypothyroidism thereby leading to increased HDL2 
levels
29. 
An increasing number of patients with SCH are 
being detected by the widespread use of TSH 
screening. However, until now, no direct 
association between SCH and atherosclerosis has 
been proven
6,30,31 and whether SCH should be 
treated for the risk of cardiovascular disease is 
controversial
32. A few studies
33,34 have suggested Saini et al / Association between different degrees of Hypothyroidism and Serum Lipids 
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that the majority of patients with SCH did not 
differ from controls in risk factors for coronary 
heart disease. In this respect, in our study, patients 
with SCH had only moderate increase in TC 
(p<0.05), whereas other lipid profile parameters did 
not differ significantly when compared with control 
individuals. 
 
CONCLUSION 
 
Our study concludes that overt hypothyroidism is a 
major cause of secondary dyslipidemia as it is 
associated with increase in the levels of total 
cholesterol, LDL-C, VLDL-C and triglycerides 
which may lead to increased cardiac risk. Our study 
also shows high prevalence of hypothyroidism in 
women of reproductive age group which is a cause 
of serious concern due to its effects during 
pregnancy and its association with dyslipidemia. 
Subclinical hypothyroidism has only a moderate 
increase in total cholesterol. Further, as SCH 
progresses to OH, there is gradual derangement of 
lipid profile. Thus, patients with dyslipidemia 
should be screened for hypothyroidism before 
being given specific lipid-lowering drug therapy. It 
seems that thyroid hormone replacement, if used, 
would be most beneficial in patients with OH 
instead of SCH. 
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